本页面由Tiger Trade Technology Pte. Ltd.提供服务

Disc Medicine

58.75
-1.2350-2.06%
成交量:33.12万
成交额:1,958.84万
市值:22.42亿
市盈率:-9.77
高:59.90
开:59.89
低:58.08
收:59.98
52周最高:99.50
52周最低:30.82
股本:3,816.01万
流通股本:3,288.51万
量比:0.83
换手率:1.01%
股息:- -
股息率:- -
每股收益(TTM):-6.0116
每股收益(LYR):-6.0116
净资产收益率:-35.86%
总资产收益率:-22.55%
市净率:3.03
市盈率(LYR):-9.77

数据加载中...

公司资料

公司名字:
Disc Medicine
交易所:
NASDAQ
成立时间:
2017
员工人数:
155
公司地址:
321 Arsenal Street,Suite 101,Watertown,Massachusetts,United States
邮编:
02472
电话:
传真:
- -
简介:
Disc Medicine,Inc.于2020年6月25日作为特拉华州公司注册成立。该公司是一家临床阶段的生物制药公司,专注于为严重血液疾病开发新型疗法。其研发管线针对红细胞生成和功能中的基本生物学通路,主要候选药物bitopertin正被开发用于治疗红细胞生成性卟啉症,其他候选药物则针对贫血及相关疾病。

董事

名称
职位
Donald W. Nicholson
Executive Chairman of the Board
John D. Quisel
Director, President and Chief Executive Officer
Georges Gemayel
Independent Director
Kevin Bitterman
Independent Director
Liam Ratcliffe
Independent Director
Mark Chin
Independent Director
William R. White
Independent Director
Nadim Ahmed
Director

股东

名称
职位
John D. Quisel
Director, President and Chief Executive Officer
Jonathan Yu
Chief Operating Officer
Jean M. Franchi
Principal Accounting Officer, Chief Financial Officer and Treasurer
Donald W. Nicholson
Executive Chairman of the Board
Pamela Stephenson
Chief Commercial Officer
Rahul Khara
Chief Legal Officer
William Savage
Chief Medical Officer